Last year was marked with massive restructuring for Glaxo. While the company merged with SmithKline Pharma in line with the global merger, the company revisited almost every aspect of its business to focus on profitability going forward. The company tried to flip every possible costs, discontinued with its rural operations. changed the organisational structure, completely restructured its product portfolio to exit competitive segments and focus on high margin brands. A new management team has also been put in place. The financials of the company are to viewed considering this backdrop.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
*- Excl. extra-ordinary items
The above financials are not comparable on a like to like basis as the last year's figures unlike current year's are not on a consolidated basis with SmithKline Pharma. Considering comparative numbers (as shown in the table below), sales and profitability have shown a de-growth. However, one interesting analysis after putting 9 months figures into consideration. While sales have not shown any improvement in the fourth quarter, there seems to be a sharp improvement in the profitability of the company. PBT margins have jumped from 9.1% for 9 months ended Sept'01 to 14.8% for the fourth quarter. This implies that the restructuring exercise of the company has already started showing results.
Consolidated Results- Restructuring paying off
PBT Margins (%)
Net Profit (Before Exceptional Items)
Consolidated sales and PBT numbers are more or less in line with our expectations. However, the company has earmarked the entire VRS cost in the current year, as against a two year spread factored in our estimates. Again the absolute VRS expense have also overshooted our estimates of Rs 850 m. Profit on sale of property is on account of partial sale of Worli land to HSBC. Remaining land is expected to fetch the company another Rs 3 bn in the current year.
The Extra-ordinary Effect
Voluntary Retirement Schemes
Restructuring / Integration Expenses
Profit on sale of property
Profit on sale of brands
Taxation Effect on extraordinary Items
GSK has been one of the major beneficiary of the recent DPCO dilution. Some of the company's top selling brands like Zentac, Zevit, Cobadex, Septrum and the entire vaccine portfolio is expected to come out of DPCO control. Considering strong brand equity, the company could benefit from price increase. At 18x forward earnings (CMP-Rs 350) for FY03 (Dec'02), the stock looks fairly priced at current valuations. However, one can expect the company to give a handsome one time dividend from expected property sale.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407